Wolfe Research upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) to a strong-buy rating in a report ...

Wolfe Research started coverage on shares of Amgen (NASDAQ:AMGN – Free Report) in a report published on Friday, MarketBeat reports. The brokerage issued a peer perform rating on the medical research ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of BioMarin Pharmaceutical (NasdaqGS:BMRN) with a ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Pfizer (NYSE:PFE) with a Underperform ...

Wolfe projects a positive outlook for Pharma & Large-Cap Biotech stocks despite potential policy changes as part of Make America Healthy Again movement. Read more here.

Wolfe Research initiated coverage of Veracyte (VCYT) with an Outperform rating and $50 price target Published first on TheFly – the ...

As previously reported, Wolfe Research analyst Doug Schenkel initiated coverage of Grail (GRAL) with a Peer Perform rating and no price target ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.09% of ...

Wolfe Research has recently raised Warner Bros Discovery Inc (WBD) stock to Peer Perform rating, as announced on November 11, 2024, according to Finviz. Earlier, on August 13, 2024, Bernstein had ...

Voters really don't like inflation. In fact, whenever there's a sustained jump in the cost of living, the party in power ...

Wolfe Research has upgraded Warner Bros. Discovery ( WBD, Financials) to "peer perform" from "underperform," citing a ...

Wolfe Research upgrades Warner Bros. Discovery to peer perform, citing potential for stable EBITDA and debt reduction through ...